Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
1.680
+0.050 (3.07%)
At close: Feb 21, 2025, 4:00 PM
1.740
+0.060 (3.57%)
After-hours: Feb 21, 2025, 5:41 PM EST
Channel Therapeutics Employees
As of December 31, 2023, Channel Therapeutics had 8 total employees, including 4 full-time and 4 part-time employees. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$1,258,470
Market Cap
10.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CHRO News
- 2 months ago - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - GlobeNewsWire
- 2 months ago - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - GlobeNewsWire
- 3 months ago - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - GlobeNewsWire
- 4 months ago - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - GlobeNewsWire
- 4 months ago - Chromocell Announces Amendment to Stock Repurchase Plan - GlobeNewsWire
- 5 months ago - Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewsWire
- 7 months ago - Chromocell Announces Stock Repurchase Plan - GlobeNewsWire
- 7 months ago - Chromocell to Participate in the Virtual Investor Lunch Break Series - GlobeNewsWire